PMID- 9048924
OWN - NLM
STAT- MEDLINE
DCOM- 19970326
LR  - 20190722
IS  - 0340-6717 (Print)
IS  - 0340-6717 (Linking)
VI  - 99
IP  - 2
DP  - 1997 Feb
TI  - Chromosomal abnormalities in sperm from testicular cancer patients before and 
      after chemotherapy.
PG  - 214-8
AB  - Sperm chromosome abnormalities were assessed in testicular cancer patients before 
      and after treatment with BEP (bleomycin, etoposide, cisplatin). The frequencies 
      of disomy for chromosomes 1, 12, X, Y and XY were assessed along with diploid 
      frequencies and sex ratios by multicolour fluorescence in situ hybridization 
      (FISH). For each cancer patient, a minimum of 10,000 sperm was assessed for each 
      chromosome probe before and after chemotherapy (CT). Data was analysed "blindly" 
      by coding the slides. A total of 161097 sperm were analyzed, 80,445 before and 
      80,642 after treatment. The mean disomy frequencies were 0.11% pre-CT vs 0.06% 
      post-CT for chromosome 1, 0.18% vs 0.15% for chromosome 12, 0.10% vs 0.9% for the 
      X chromosome, 0.13% vs 0.10% for the Y chromosome and 0.25% vs 0.20% for XY 
      sperm. There was no significant difference in the frequency of disomy pre-CT vs 
      post-CT for any chromosome except that chromosome 1 demonstrated a significant 
      decrease after CT. The "sex ratios" and frequency of diploid sperm were also not 
      significantly different in pre and post-CT samples with 50.2% X-bearing sperm 
      pre-CT and 50.5% X post-CT and 0.14% diploid sperm pre-CT vs 0.15% diploid sperm 
      post-CT. There was no significant donor heterogeneity among the cancer patients. 
      None of the values in the cancer patients differed significantly from 10 normal 
      control donors. Thus our study suggests that BEP chemotherapy does not increase 
      the risk of numerical chromosomal abnormalities in human sperm.
FAU - Martin, R H
AU  - Martin RH
AD  - Department of Genetics, Alberta Children's Hospital, Calgary, Canada. 
      renee@ach.ucalgary.ca
FAU - Ernst, S
AU  - Ernst S
FAU - Rademaker, A
AU  - Rademaker A
FAU - Barclay, L
AU  - Barclay L
FAU - Ko, E
AU  - Ko E
FAU - Summers, N
AU  - Summers N
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Hum Genet
JT  - Human genetics
JID - 7613873
RN  - 11056-06-7 (Bleomycin)
RN  - 6PLQ3CP4P3 (Etoposide)
RN  - Q20Q21Q62J (Cisplatin)
RN  - BEP protocol
SB  - IM
MH  - Adult
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
MH  - Bleomycin/administration & dosage
MH  - Carcinoma, Embryonal/drug therapy/*genetics/ultrastructure
MH  - *Chromosome Aberrations
MH  - Cisplatin/administration & dosage
MH  - Etoposide/administration & dosage
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Spermatozoa/*drug effects/ultrastructure
MH  - Testicular Neoplasms/drug therapy/*genetics/ultrastructure
EDAT- 1997/02/01 00:00
MHDA- 1997/02/01 00:01
CRDT- 1997/02/01 00:00
PHST- 1997/02/01 00:00 [pubmed]
PHST- 1997/02/01 00:01 [medline]
PHST- 1997/02/01 00:00 [entrez]
AID - 10.1007/s004390050342 [doi]
PST - ppublish
SO  - Hum Genet. 1997 Feb;99(2):214-8. doi: 10.1007/s004390050342.